CMML Clinical Trial
Official title:
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients With Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients
To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)
This is a Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02581007 -
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
|
Phase 2 | |
| Completed |
NCT03526666 -
Ascorbic Acid Levels in MDS, AML, and CMML Patients
|
||
| Completed |
NCT06267898 -
Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML
|
||
| Active, not recruiting |
NCT04806906 -
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients
|
Phase 2 | |
| Recruiting |
NCT05184842 -
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
|
Phase 2 | |
| Recruiting |
NCT05153226 -
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
|
Phase 3 | |
| Active, not recruiting |
NCT04139434 -
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
|
Phase 1 | |
| Completed |
NCT02193958 -
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04358393 -
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
|
Phase 1/Phase 2 | |
| Completed |
NCT01261312 -
SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
|
Phase 1/Phase 2 | |
| Completed |
NCT02323178 -
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04473911 -
Haplo Peripheral Blood Sct In GVHD Prevention
|
Phase 1 | |
| Recruiting |
NCT04730258 -
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
|
Phase 1/Phase 2 | |
| Terminated |
NCT02418000 -
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
|
Phase 1/Phase 2 |